Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after 12 years in management at Japan's biggest ...

In addition, it is essential to note that Schrödinger is advancing strategic partnerships with companies such as Ajax Therapeutics, Morphic (acquired by Eli Lilly (NYSE: LLY)), Nimbus ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...

On Monday, there were two: GSK bought IDRx for $1 billion upfront, and Lilly acquired Scorpion Therapeutics’ principal drug for up to $2.5 billion. — Gwendolyn Wu ...